Aspirin Could Prevent Common, Dangerous Condition of Pregnancy
|
Tweet
|
|
Low-dose aspirin therapy may be effective in the treatment of pre-eclampsia, a dangerous pregnancy condition, suggests a new study led by Queen’s University researcher Colin Funk, published in the international Journal of Clinical Investigation.
This treatment strategy is controversial, since it has been associated with complications—such as thrombosis (blood clotting) and problems with labor.
However, “the rationale for low-dose aspirin therapy to prevent or delay pre-eclampsia without compromising reproductive function, or increasing the possibility of thrombosis, is definitely a feasible therapeutic strategy,” based on findings in the new study, says Dr. Funk.
Pre-eclampsia Affects 5%-10% of All Pregnancies
Pre-eclampsia, which strikes five to 10 per cent of all pregnancies, is characterized by High Blood Pressure in the mother, and is one of the leading causes of baby and maternal deaths in developing countries.
It is believed that the development of new treatments for pre-eclampsia and the early identification and management of this risk may prevent the onset of long-term heart disease.
Normal Labors, Litters in Mice
In the current study, the research team created a model that mimics low-dose aspirin therapy in mice. They found that the uterine and ovarian environments were altered only slightly, and the mice experienced normal induction of labor, normal litter size, and normal development of offspring.
“This new mouse model will have significant value in studying the implications of low-dose aspirin in several pathological conditions, such as pre-eclampsia, thrombosis and inflammatory disorders,” says Dr. Funk. “We’re hopeful that our model will lead the way to further treatment options for these debilitating conditions.”
Molecular Medicine Expert
Recently appointed as Canada Research Chair in Molecular, Cellular and Physiological Medicine, Dr. Funk is an expert in the study of molecules that function in almost every bodily system.
Other members of the research team are from the University of Pennsylvania, where Dr. Funk was on faculty before coming to Queen’s through a Canadian Institutes of Health Research (CIHR) program.
Revision date: June 14, 2011
Last revised: by Dave R. Roger, M.D.
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
- Full Story - - »»»
Best time for a coffee break? There’s an app for that
- Full Story - - »»»
Cellphone Use Linked to Selfish Behavior in UMD Study
- Full Story - - »»»
Optimism about heart risks may be a good thing
- Full Story - - »»»
New guidelines developed for improved DVT diagnosis
- Full Story - - »»»
Teen pregnancy, abortion rates at record low, study says
- Full Story - - »»»
Think you can’t get pregnant? Try again, study says
- Full Story - - »»»

